Navigation Links
Nausea Drug Shows Promise Against Opioid Addiction
Date:2/18/2009

Ondansetron relieves withdrawal symptoms without side effects, early study shows

WEDNESDAY, Feb. 18 (HealthDay News) -- A drug currently used to treat nausea can prevent symptoms of withdrawal from illegal and prescription opioid drugs such as heroin, morphine and codeine, a new study shows.

The Stanford University scientists behind the research added it can do so without some of the serious side effects caused by existing treatments for addiction to these drugs.

Initial tests in mice showed that the drug ondansetron (Zofran) blocks certain 5-HT3 receptors involved in withdrawal symptoms, the researchers said. They then tested it in eight healthy, non-opioid-dependent volunteers who were given two doses of morphine, once without ondansetron and one with it, and found ondansetron reduced withdrawal symptoms in humans.

The study appears in the Feb. 17 online issue of the Journal of Pharmacogenetics and Genomics.

"Opioid abuse is rising at a faster rate than any other type of illicit drug use, yet only about a quarter of those dependent on opioids seek treatment. One barrier to treatment is that when you abruptly stop taking the drugs, there is a constellation of symptoms associated with withdrawal," lead author Dr. Larry F. Chu, an assistant professor of anesthesia, said in a Stanford news release.

Those symptoms include agitation, insomnia, diarrhea, nausea and vomiting. Current methods of treating withdrawal symptoms aren't completely effective or cause severe side effects, requiring constant patient supervision.

"What we need is a magic bullet, something that treats the symptoms of withdrawal, does not lead to addiction and can be taken at home," Chu added.

The Stanford team plans to continue testing the effectiveness of ondansetron in treating opioid addiction and to conduct a clinical study to determine the effectiveness of an ondansetron-like drug in treating opioid addiction.

However, the researchers noted that ondansetron alone can't solve the problems caused by opioid addiction, which is a long-term, complex process that involves both physical and psychological factors.

"This is not a cure for addiction. It's naive to think that any one receptor is a panacea for treatment. Treating the withdrawal component is only one way of alleviating the suffering. With luck and determination, we can identify additional targets and put together a comprehensive treatment program," principal investigator Dr. J. David Clark, a professor of anesthesia, said in the news release.

More information

The National Institutes of Health has more about opiate withdrawal.



-- Robert Preidt



SOURCE: Stanford University, news release, Feb. 17, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Oncologists Rank Aloxis Marketing Message Most Influential in the Chemotherapy-Induced Nausea and Vomiting Drug Market
2. SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available
3. FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting
4. Explaining chemotherapy-associated nausea
5. Mayo Clinic study finds FDA warning against antinausea drug droperidol unnecessary
6. Acupuncture does not reduce radiotherapy-induced nausea, but patients believe it does
7. No Link Between Anti-Nausea Drug, Heart Trouble
8. HotHead Technologies Heat Sensor Shows Exciting Potential by Kennesaw State University Researchers
9. Partnership for Prevention: CDC Report Shows Compelling Need for FDA Regulation of Tobacco
10. New CDC Study Shows Tobacco Marketing Influences Kids to Smoke, Underscores Need for FDA Regulation of Tobacco Products
11. Caregivers not receiving the help they need, study shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Nausea Drug Shows Promise Against Opioid Addiction
(Date:12/2/2016)... ... December 02, 2016 , ... More than 100 business, ... expected to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, 2016. This inaugural ... students and operating support to UNCF-member institutions, including Miles College, Oakwood University, Tuskegee ...
(Date:12/2/2016)... ... 2016 , ... FlexiSpot, a trusted name in sit-stand solutions ... for all of the company’s desktop riser products. A simple application form and ... FlexiSpot’s unique desktop risers use an advanced dual gas spring hovering system to ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... The annual ... Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who ... C) or prescription drug plan (Part D) need to make changes during this period ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs ... patients must find the one that works for them. When an inventor from Suisun ... that worked and decided to share it with others. , He developed a prototype ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. ... will be included in the 2016 “Guide to America’s Top Plastic Surgeons” for ... the amalgamation of their education, experience, and professional associations. , One the ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... -- On Thursday, the NASDAQ Composite and the ... Dow Jones Industrial Average managed to stay in green. Losses ... prompted Stock-callers this morning to look at the performances of ... ), Smith & Nephew PLC (NYSE: SNN ), ... Therapeutics Inc. (NASDAQ: KOOL ). You can access ...
(Date:12/2/2016)... 2016 Research and Markets has announced ... Cancer - Technologies, Markets and Companies" to their offering. ... , , ... cancer The market value of drug delivery technologies and ... 2015-2025 are given according to organs involved and the types of ...
(Date:12/2/2016)... Conn. , Dec. 1, 2016  Today, Simpson ... announced the honor of being selected as winners of ... Simpson Healthcare Executives Website at the PLATINUM level, Blue ... Training Module at the GOLD Level, and our proprietary ... At Simpson Healthcare Executives, we are excited to ...
Breaking Medicine Technology: